Microbiome Times Partnering Forum: Meet Your Next Collaborator

Connect with decision-makers spanning the global microbial ecosystem to propel dealmaking and innovation

500+ expected attendees from over 30 countries

Dome Event Hall, Brussels, 18-19 March 2025

In collaboration with

Meet Dealmakers from biotech, VCs, consumer care and pharma

This two-day event expects to see over 50 expert speakers and over 500 delegates descend on Brussels, 18-19 March to uncover the latest in microbial product innovation. Organised by Microbiome Times Magazine, the leading industry trade journal. the MT Partnering Forum will explore the industry’s latest trends, scientific advancements, challenges, and opportunities to accelerate the development of novel microbial-based products.

Free-to-attend for start-ups, academic innovators, investors and healthcare companies, Microbiome Times Forum provides attendees with the opportunity to meet their next collaborator, partner or customer by scheduling over 30 one-to-one meetings through our tailor-made partnering platform,

MT Forum Advisory Board

Daniel Couto

Chief Operating Officer

Denise Kelly

Investment Advisor

Adam Baker

Director of Science

Luis Gosálbez

Managing Director

Marie Drago

Chief Creative Officer

Karoline Faust

Associate Professor

Nikole Kimes

Founder & CEO

Emily White

Chief Editor

Amine Zorgani

Owner

Sam Possemiers

Chief Executive Officer

Herve Affagard

Founder & CEO

George Paraskevakos

Executive Director

Aurore Matton

M&A Manager

Robert E. Steinert

Principal Scientist

Anna Beatriz Ferreira

Global R&D Specialist

Cheri Ackerman

Cofounder & CEO

Sarah Lebeer

Full Professor

Travis Whitfill

COO

In collaboration with…

The goal of the EMIH is to promote medical innovation, based on the microbiota, as one of the public health priorities within the European Union. Its members are committed to developing advances in therapeutic, diagnostics and medical bioproduction based on the microbiota, in the field of human health, through a framework meeting the highest quality standards and also allowing economic balance, in order to maintain therapeutic innovation.

Through a collective voice, the MTIG membership works together to enhance the regulatory, investment, and commercial environment to accelerate microbiome therapeutic product development and expand availability of life-changing and life-saving FDA approved microbiome therapies to patients.

Partnering. Networking. Industry Insights.

“MTIG looks forward to supporting the inaugural Microbiome Times Partnering Forum. Our members are committed to fostering dialogue with stakeholders in the microbiome space to accelerate collaboration and innovation, and believe this event will serve as a venue to do just that.”

Nik Kimes, Chairman at MTIG and CEO at Siolta Therapeutics

“The microbiome-based therapies sector has specific challenges like for any emerging field. Recent progress towards late-stage clinical trials is encouraging and we see signs of increased maturity. In this context, unity is strength. Microbiome Times' annual event is a unique opportunity to highlight key industry players and foster fruitful collaborations that can advance this critical field”

Hervé Affagard. President of EMIH and CEO of Maat Pharma

  • Start-up & Innovator Pitches

    Get the scoop on the latest innovative products and services from start-up biotechs, academic innovators and research partners.

  • Partnering

    Use our tailor-made dedicated one-to-one partnering platform to schedule private meetings throughout the event.

  • Networking

    With multiple on and off site dedicated networking time and events, such as dinners, lunches, evening receptions, take advantage of multiple opportunities to connect with industry piers in a casual setting.

  • Industry Insights

    The program is designed to address the latest trends, challenges and opportunities in microbiome. Hear from industry & science leaders to identify your next business move.

How to Attend

Industry & Academic Innovators

Free (Until 31 October)

Pre-revenuecompanies developing microbiome-based products (pharmaceuticals, cosmetics, food supplements)

Academics planning to commercialise their research

Investors/ Healthcare/ Pharma

Free (Until 31 October)

Companies active or interested in licensing or investing in new products/ technologies

Service Providers

€950 (Until 31 October)

€1,450 (From 1 November onwards)

Companies providing products and or services for microbiome research or product development (sequencing companies, CDMOs, CROs, equipment providers, consultancies

Industry

Free (Until 31 October)

Revenue companies that have developed a product for/ from microbiome for human heath (cosmetics, drugs, food supplements)